Amneal Pharmaceuticals, Inc. Class A Common Stock Asset Resilience Ratio
Amneal Pharmaceuticals, Inc. Class A Common Stock asset resilience ratio. Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has an Asset Resilience Ratio of 0.05% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Amneal Pharmaceuticals, Inc. Class A Com defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2024)
Asset resilience ratio of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2024. This chart shows how Amneal Pharmaceuticals, Inc. Class A Common Stock's Asset Resilience Ratio has changed over time. Read Amneal Pharmaceuticals, Inc. Class A Com debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Amneal Pharmaceuticals, Inc. Class A Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Amneal Pharmaceuticals, Inc. Class A Com's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.87 Million | 0.05% |
| Total Liquid Assets | $1.87 Million | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Amneal Pharmaceuticals, Inc. Class A Common Stock maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Amneal Pharmaceuticals, Inc. Class A Common Stock Industry Peers by Asset Resilience Ratio
Compare Amneal Pharmaceuticals, Inc. Class A Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.23% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.95% |
|
Ajanta Pharma Limited
NSE:AJANTPHARM |
Drug Manufacturers - Specialty & Generic | 14.99% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728 |
Drug Manufacturers - Specialty & Generic | 9.66% |
Amneal Pharmaceuticals, Inc. Class A Common Stock Asset Resilience Ratio by Year (2015–2024)
Amneal Pharmaceuticals, Inc. Class A Common Stock asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Amneal Pharmaceuticals, Inc. Class A Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.05% | $1.87 Million | $3.50 Billion | -0.01pp |
| 2023-12-31 | 0.06% | $2.20 Million | $3.47 Billion | +0.02pp |
| 2022-12-31 | 0.05% | $1.82 Million | $3.80 Billion | +0.02pp |
| 2021-12-31 | 0.03% | $1.17 Million | $3.94 Billion | -0.01pp |
| 2020-12-31 | 0.04% | $1.70 Million | $4.01 Billion | +0.01pp |
| 2019-12-31 | 0.03% | $1.12 Million | $3.67 Billion | -0.02pp |
| 2018-12-31 | 0.05% | $2.14 Million | $4.35 Billion | -0.09pp |
| 2017-12-31 | 0.14% | $1.85 Million | $1.34 Billion | -0.22pp |
| 2016-12-31 | 0.36% | $4.35 Million | $1.22 Billion | -0.13pp |
| 2015-12-31 | 0.49% | $4.98 Million | $1.01 Billion | -- |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms … Read more